ACC
MCID: ADR016
MIFTS: 62

Adrenal Cortical Carcinoma (ACC)

Categories: Cancer diseases, Endocrine diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

MalaCards integrated aliases for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 40 12
Adrenocortical Carcinoma 40 12 74 20 29 6 44 15
Carcinoma of the Adrenal Cortex 12
Carcinoma Adrenocortical 54
Adrenal Cortex Carcinoma 17
Adrenocortical Cancer 54
Acc 20

Classifications:



Summaries for Adrenal Cortical Carcinoma

GARD : 20 Adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex). These glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. Adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. Girls are more often affected than boys. Symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension, weight gain, frequent urination and possibly deepening of the voice. These symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. Adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. There are a number of genes that have changes (mutations) that can cause an adrenocortical carcinoma, including TP53 and IGF2. There have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. An adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol, the hormone released by the adrenal glands. Blood tests can also be conducted to measure levels of potassium and sodium in the blood. A CT scan or MRI may be used to search for a visible tumor in the adrenal cortex. Treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. Chemotherapy, specifically a drug called mitotane, can be used to try to remove any remaining cancer after surgery.

MalaCards based summary : Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to conn's syndrome and li-fraumeni syndrome, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Carcinoma is MIR483 (MicroRNA 483), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Toll-like Receptor Signaling Pathway. The drugs Lenograstim and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and adrenal gland, and related phenotypes are adrenocortical carcinoma and hyperhidrosis

Disease Ontology : 12 An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia : 74 Adrenocortical carcinoma (ACC) is an aggressive cancer originating in the cortex (steroid... more...

Related Diseases for Adrenal Cortical Carcinoma

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 conn's syndrome 31.2 PRKAR1A MC2R HSD11B2 GNAS CHGA
2 li-fraumeni syndrome 31.0 TP53 PRKAR1A PIK3CA MIR483 IGF2 CTNNB1
3 hemihyperplasia, isolated 30.9 IGF2 H19
4 adenoma 30.9 TP53 PRKAR1A PIK3CA HSD11B2 GNAS CTNNB1
5 thyroid carcinoma 30.9 PIK3CA H19 BRAF
6 beckwith-wiedemann syndrome 30.8 TP53 PRKAR1A MIR483 IGF2 H19 GNAS
7 adrenal carcinoma 30.7 TP53 PRKAR1A PIK3CA NRAS NR5A1 MIR483
8 adrenal cortical adenoma 30.7 PRKAR1A NR5A1 MIR483 MC2R IGF2 CTNNB1
9 acinar cell carcinoma 30.7 TP53 IGF2 CTNNB1 CHGA
10 adrenal adenoma 30.6 PRKAR1A MIR483 MC2R IGF2 HSD11B2 GNAS
11 multiple endocrine neoplasia, type i 30.6 PRKAR1A MIR483 GNAS CHGA
12 endometrial cancer 30.6 TP53 PIK3CA NRAS IGF2 H19 CTNNB1
13 renal cell carcinoma, nonpapillary 30.5 TP53 PIK3CA NRAS MIR214 MIR195 H19
14 melanoma, cutaneous malignant 1 30.5 TP53 NRAS CTNNB1 BRAF
15 hemangioma 30.5 TP53 IGF2 CTNNB1 CHGA
16 body mass index quantitative trait locus 11 30.5 TP53 NR5A1 MIR483 MC2R IGF2 HSD11B2
17 melanoma 30.5 TP53 PIK3CA NRAS MIR184 H19 GNAS
18 carney complex variant 30.5 PRKAR1A MIR483 MC2R GNAS CTNNB1
19 lynch syndrome 30.4 TP53 PIK3CA NRAS CTNNB1 BRAF
20 gastrointestinal stromal tumor 30.4 TP53 IGF2 CHGA BRAF
21 adenocarcinoma 30.4 TP53 PIK3CA H19 GNAS CTNNB1 BRAF
22 primary pigmented nodular adrenocortical disease 30.4 PRKAR1A MIR483 MC2R GNAS CTNNB1 CHGA
23 islet cell tumor 30.4 MIR483 IGF2 CHGA
24 thyroid tumor 30.4 PRKAR1A BRAF
25 rhabdomyosarcoma 30.4 TP53 PIK3CA NRAS IGF2 H19 CTNNB1
26 sarcoma 30.4 TP53 PIK3CA NRAS CTNNB1 BRAF
27 thyroid carcinoma, familial medullary 30.3 PRKAR1A CHGA BRAF
28 acth-independent macronodular adrenal hyperplasia 30.3 PRKAR1A MIR483 MC2R GNAS
29 acth-independent cushing syndrome 30.3 PRKAR1A GNAS
30 peutz-jeghers syndrome 30.3 TP53 PRKAR1A GNAS CTNNB1
31 pituitary adenoma, prolactin-secreting 30.3 PRKAR1A NR5A1 GNAS CHGA
32 carcinosarcoma 30.3 TP53 PIK3CA CTNNB1
33 hepatoblastoma 30.3 TP53 MIR483 IGF2 H19 CTNNB1
34 ovary adenocarcinoma 30.3 TP53 PIK3CA GNAS CTNNB1 BRAF
35 malignant astrocytoma 30.3 TP53 H3-3A CTNNB1 CHGA BRAF
36 wilms tumor 1 30.3 TP53 NR5A1 MIR483 IGF2 H19 CTNNB1
37 neuroblastoma 30.2 TP53 PIK3CA NRAS MIR184 IGF2 H19
38 adrenal rest tumor 30.2 NR5A1 MC2R
39 kidney cancer 30.2 TP53 PIK3CA MIR214 H19
40 squamous cell carcinoma 30.1 TP53 PIK3CA H19 GNAS CTNNB1 BRAF
41 lung cancer susceptibility 3 30.1 TP53 PIK3CA NRAS MIR483 H19 GNAS
42 hepatocellular carcinoma 29.9 TP53 PIK3CA NRAS MIR503 MIR483 MIR214
43 squamous cell carcinoma, head and neck 29.9 TP53 PIK3CA MIR214 MIR195 H19 GNAS
44 pancreatic cancer 29.8 TP53 PIK3CA MIR483 MIR214 MIR195 H19
45 lentigines 29.8 PRKAR1A BRAF
46 lung cancer 29.4 TP53 PIK3CA NRAS MIR511 MIR503 MIR483
47 aplasia cutis congenita, nonsyndromic 11.5
48 corpus callosum, agenesis of 11.4
49 adrenocortical carcinoma with pure aldosterone hypersecretion 11.3
50 adenoid cystic carcinoma 11.3

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to Adrenal Cortical Carcinoma

Symptoms & Phenotypes for Adrenal Cortical Carcinoma

Human phenotypes related to Adrenal Cortical Carcinoma:

31 (show all 26)
# Description HPO Frequency HPO Source Accession
1 adrenocortical carcinoma 31 obligate (100%) HP:0006744
2 hyperhidrosis 31 frequent (33%) HP:0000975
3 diabetes mellitus 31 frequent (33%) HP:0000819
4 hypertension 31 frequent (33%) HP:0000822
5 muscle weakness 31 frequent (33%) HP:0001324
6 hypokalemia 31 frequent (33%) HP:0002900
7 anxiety 31 frequent (33%) HP:0000739
8 irritability 31 frequent (33%) HP:0000737
9 abdominal pain 31 frequent (33%) HP:0002027
10 striae distensae 31 frequent (33%) HP:0001065
11 hyperaldosteronism 31 frequent (33%) HP:0000859
12 weight loss 31 frequent (33%) HP:0001824
13 abnormality of reproductive system physiology 31 frequent (33%) HP:0000080
14 lung adenocarcinoma 31 frequent (33%) HP:0030078
15 adrenocorticotropic hormone deficiency 31 frequent (33%) HP:0011748
16 hypertrichosis 31 frequent (33%) HP:0000998
17 increased body weight 31 frequent (33%) HP:0004324
18 palpitations 31 frequent (33%) HP:0001962
19 increased urinary cortisol level 31 frequent (33%) HP:0012030
20 paradoxical increased cortisol secretion on dexamethasone suppression test 31 frequent (33%) HP:0003466
21 increased serum estradiol 31 frequent (33%) HP:0025134
22 panic attack 31 frequent (33%) HP:0025269
23 increased serum androstenedione 31 frequent (33%) HP:0025380
24 elevated serum 11-deoxycortisol 31 frequent (33%) HP:0025436
25 abnormal serum dehydroepiandrosterone level 31 frequent (33%) HP:0500022
26 abnormality of urine homeostasis 31 occasional (7.5%) HP:0003110

UMLS symptoms related to Adrenal Cortical Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 BRAF CHGA GNAS H19 HSD11B2 IGF2

MGI Mouse Phenotypes related to Adrenal Cortical Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 BRAF CHGA CTNNB1 GNAS HSD11B2 IGF2
2 endocrine/exocrine gland MP:0005379 10 BRAF CHGA CTNNB1 GNAS IGF2 MC2R
3 muscle MP:0005369 9.81 BRAF CHGA CTNNB1 GNAS HSD11B2 IGF2
4 neoplasm MP:0002006 9.56 BRAF CTNNB1 GNAS HSD11B2 NRAS PIK3CA
5 no phenotypic analysis MP:0003012 9.17 CHGA CTNNB1 GNAS IGF2 NRAS PIK3CA

Drugs & Therapeutics for Adrenal Cortical Carcinoma

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6 Antineoplastic Agents, Hormonal Phase 3
7 Antibiotics, Antitubercular Phase 3
8
Liposomal doxorubicin Phase 3 31703
9 Anti-Bacterial Agents Phase 3
10 Insulin, Globin Zinc Phase 3
11 Mitogens Phase 3
12 insulin Phase 3
13 Keratolytic Agents Phase 3
14 Etoposide phosphate Phase 3
15 Antimitotic Agents Phase 3
16 Dermatologic Agents Phase 3
17 Tubulin Modulators Phase 3
18 Podophyllotoxin Phase 3 518-28-5
19
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
20
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
21
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
22
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
25
Sodium citrate Approved, Investigational Phase 2 68-04-2
26
Tamoxifen Approved Phase 2 10540-29-1 2733526
27
Lactitol Approved, Investigational Phase 2 585-86-4 157355
28
acetic acid Approved Phase 2 64-19-7 176
29
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
30
Ipilimumab Approved Phase 2 477202-00-9
31
Mitotane Approved Phase 2 53-19-0 4211
32
Pembrolizumab Approved Phase 2 1374853-91-4
33
nivolumab Approved Phase 2 946414-94-4
34
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
35
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
36
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
37
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
39 Gossypol Investigational Phase 2 303-45-7
40
Suramin Investigational Phase 2 145-63-1 5361
41 polysaccharide-K Phase 2
42 Immunologic Factors Phase 2
43 Liver Extracts Phase 2
44 Citrate Phase 2
45 Estrogens Phase 2
46 Estrogen Receptor Antagonists Phase 2
47 Estrogen Antagonists Phase 2
48 Estrogen Receptor Modulators Phase 2
49 retinol Phase 2
50 Retinol palmitate Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Unknown status NCT00777244 Phase 3 MITOTANE
2 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Unknown status NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
4 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
5 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
6 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
7 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
8 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
9 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
10 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
11 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
12 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
13 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
14 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
15 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
16 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
17 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
18 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
19 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
20 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
21 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
22 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
23 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
24 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Recruiting NCT04187404 Phase 1, Phase 2
25 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
26 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
27 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
28 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
29 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
30 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
31 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
32 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
33 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
34 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
35 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
36 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
37 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
38 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
39 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
40 A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications Completed NCT01772004 Phase 1 Avelumab
41 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
42 A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
43 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
44 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
45 A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease Completed NCT00436657 Phase 1 CHPP of Cisplatin
46 A Phase 1b, Open-Label Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production Recruiting NCT04373265 Phase 1 Relacorilant;Pembrolizumab
47 A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors Active, not recruiting NCT02637531 Phase 1 IPI-549 (eganelisib);Nivolumab
48 A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma Terminated NCT01832974 Phase 1 IL-13-PE
49 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
50 Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma Unknown status NCT00457587

Search NIH Clinical Center for Adrenal Cortical Carcinoma

Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

Genetic tests related to Adrenal Cortical Carcinoma:

# Genetic test Affiliating Genes
1 Adrenocortical Carcinoma 29

Anatomical Context for Adrenal Cortical Carcinoma

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

40
Cortex, Adrenal Cortex, Adrenal Gland, Liver, Thyroid, Breast, Kidney

Publications for Adrenal Cortical Carcinoma

Articles related to Adrenal Cortical Carcinoma:

(show top 50) (show all 3116)
# Title Authors PMID Year
1
Li-Fraumeni syndrome in a Turkish family. 61 54
20426520 2010
2
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. 61 54
19649631 2010
3
Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome. 61 54
20017945 2009
4
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. 47
19996210 2009
5
Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. 47
19546168 2009
6
Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. 61 54
19318454 2009
7
Nestin as a marker in the classification of adrenocortical tumors. 54 61
19294612 2009
8
[Identification of a novel TP53 germline mutation in one child with adrenocortical carcinoma]. 61 54
19671334 2009
9
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. 54 61
19204208 2009
10
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells. 61 54
19026713 2009
11
p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma. 54 61
19714490 2009
12
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. 54 61
18854392 2009
13
Germline p53 mutation in a Micronesian child with adrenocortical carcinoma and subsequent osteosarcoma. 54 61
18989156 2008
14
Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. 61 54
18713819 2008
15
Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. 61 54
18611974 2008
16
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells. 61 54
18639541 2008
17
Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. 54 61
18762572 2008
18
Effects of fifteen PBDE metabolites, DE71, DE79 and TBBPA on steroidogenesis in the H295R cell line. 54 61
18313098 2008
19
The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses. 61 54
18393131 2008
20
Expression of aromatase and estrogen receptors in human adrenocortical tumors. 54 61
18157729 2008
21
Inhibition of human placental aromatase activity by hydroxylated polybrominated diphenyl ethers (OH-PBDEs). 61 54
18022659 2008
22
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. 54 61
18086272 2008
23
Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma. 54 61
18824868 2008
24
Mono-(2-ethylhexyl) phthalate (MEHP) induces nuclear receptor 4A subfamily in NCI-H295R cells: a possible mechanism of aromatase suppression by MEHP. 54 61
17574328 2007
25
Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors. 54 61
17566092 2007
26
[Effect of insulin-like growth factor and its receptor-I antibody on growth of human adrenocortical carcinoma SW-13 cell lines in vitro]. 61 54
17259156 2007
27
In vitro effects of brominated flame retardants and metabolites on CYP17 catalytic activity: a novel mechanism of action? 54 61
16828825 2006
28
Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. 54 61
16033918 2006
29
Effect of epidermal growth factor and prostaglandin on the expression of aromatase (CYP19) in human adrenocortical carcinoma cell line NCI-H295R cells. 54 61
16394175 2006
30
Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils. 61 54
16260757 2005
31
Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells. 54 61
15907334 2005
32
Inhibition and induction of aromatase (CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells. 54 61
16177243 2005
33
Germline p53 mutation presenting as synchronous tumors. 61 54
16096528 2005
34
Clinical and molecular evidence for DAX-1 inhibition of steroidogenic factor-1-dependent ACTH receptor gene expression. 61 54
15879363 2005
35
TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives. 54 61
15878142 2005
36
Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts. 54 61
15589976 2005
37
Rhabdomyosarcoma, osteosarcoma, and adrenocortical carcinoma in a child with a germline p53 mutation. 54 61
15390294 2004
38
Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. 61 54
15319488 2004
39
Nur-related factor 1 and nerve growth factor-induced clone B in human adrenal cortex and its disorders. 61 54
15292355 2004
40
Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors. 54 61
15171718 2004
41
Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. 54 61
15241731 2004
42
Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R. 61 54
14709151 2004
43
Nonfunctioning adrenocortical carcinoma in a child. 61 54
14692192 2003
44
Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. 61 54
12668173 2003
45
Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant. 61 54
12634062 2003
46
Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. 54 61
12668216 2003
47
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. 54 61
12236151 2002
48
Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. 61 54
11869873 2002
49
Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. 54 61
11889182 2002
50
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. 61 54
11753428 2002

Variations for Adrenal Cortical Carcinoma

ClinVar genetic disease variations for Adrenal Cortical Carcinoma:

6 (show top 50) (show all 67)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.470T>C (p.Val157Ala) SNV Likely pathogenic 428887 rs1131691023 17:7578460-7578460 17:7675142-7675142
2 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu) SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
3 CTNNB1 NM_001904.4(CTNNB1):c.134C>G (p.Ser45Cys) SNV Likely pathogenic 376242 rs121913409 3:41266137-41266137 3:41224646-41224646
4 CTNNB1 NM_001904.4(CTNNB1):c.133T>C (p.Ser45Pro) SNV Likely pathogenic 17589 rs121913407 3:41266136-41266136 3:41224645-41224645
5 TP53 NM_000546.5(TP53):c.700T>A (p.Tyr234Asn) SNV Likely pathogenic 376692 rs864622237 17:7577581-7577581 17:7674263-7674263
6 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
7 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
8 TP53 NM_000546.5(TP53):c.518T>A (p.Val173Glu) SNV Likely pathogenic 376669 rs1057519747 17:7578412-7578412 17:7675094-7675094
9 TP53 NM_000546.5(TP53):c.518T>C (p.Val173Ala) SNV Likely pathogenic 376017 rs1057519747 17:7578412-7578412 17:7675094-7675094
10 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His) SNV Likely pathogenic 375947 rs397516896 7:140453155-140453155 7:140753355-140753355
11 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Likely pathogenic 17580 rs121913412 3:41266124-41266124 3:41224633-41224633
12 TP53 NM_000546.5(TP53):c.374C>A (p.Thr125Lys) SNV Likely pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
13 CTNNB1 NM_001904.4(CTNNB1):c.122C>A (p.Thr41Asn) SNV Likely pathogenic 376394 rs121913413 3:41266125-41266125 3:41224634-41224634
14 TP53 NM_000546.5(TP53):c.824G>C (p.Cys275Ser) SNV Likely pathogenic 376583 rs863224451 17:7577114-7577114 17:7673796-7673796
15 TP53 NM_000546.5(TP53):c.404G>A (p.Cys135Tyr) SNV Likely pathogenic 141762 rs587781991 17:7578526-7578526 17:7675208-7675208
16 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 17:7578412-7578412 17:7675094-7675094
17 TP53 NM_000546.5(TP53):c.404G>T (p.Cys135Phe) SNV Likely pathogenic 376559 rs587781991 17:7578526-7578526 17:7675208-7675208
18 TP53 NM_001276697.2(TP53):c.-75T>C SNV Likely pathogenic 376560 rs1057519975 17:7578527-7578527 17:7675209-7675209
19 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
20 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
21 TP53 NM_000546.5(TP53):c.374C>T (p.Thr125Met) SNV Likely pathogenic 183748 rs786201057 17:7579313-7579313 17:7675995-7675995
22 TP53 NM_000546.5(TP53):c.637C>G (p.Arg213Gly) SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
23 CTNNB1 NM_001904.4(CTNNB1):c.101G>T (p.Gly34Val) SNV Likely pathogenic 17582 rs28931589 3:41266104-41266104 3:41224613-41224613
24 CTNNB1 NM_001904.4(CTNNB1):c.101G>C (p.Gly34Ala) SNV Likely pathogenic 376390 rs28931589 3:41266104-41266104 3:41224613-41224613
25 TP53 NM_000546.5(TP53):c.403T>A (p.Cys135Ser) SNV Likely pathogenic 376562 rs1057519975 17:7578527-7578527 17:7675209-7675209
26 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely pathogenic 73058 rs121913254 1:115256530-115256530 1:114713909-114713909
27 TP53 NM_000546.5(TP53):c.403T>G (p.Cys135Gly) SNV Likely pathogenic 376563 rs1057519975 17:7578527-7578527 17:7675209-7675209
28 CTNNB1 NM_001904.4(CTNNB1):c.101G>A (p.Gly34Glu) SNV Likely pathogenic 17584 rs28931589 3:41266104-41266104 3:41224613-41224613
29 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 17:7577580-7577580 17:7674262-7674262
30 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly) SNV Likely pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
31 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro) SNV Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
32 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr) SNV Likely pathogenic 375895 rs121913409 3:41266137-41266137 3:41224646-41224646
33 TP53 NM_000546.5(TP53):c.700T>G (p.Tyr234Asp) SNV Likely pathogenic 219759 rs864622237 17:7577581-7577581 17:7674263-7674263
34 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys) SNV Likely pathogenic 127820 rs587780073 17:7577580-7577580 17:7674262-7674262
35 TP53 NM_000546.5(TP53):c.374C>G (p.Thr125Arg) SNV Likely pathogenic 376667 rs786201057 17:7579313-7579313 17:7675995-7675995
36 CTNNB1 NM_001904.4(CTNNB1):c.100G>C (p.Gly34Arg) SNV Likely pathogenic 376233 rs121913399 3:41266103-41266103 3:41224612-41224612
37 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 17:7579314-7579314 17:7675996-7675996
38 TP53 NM_000546.5(TP53):c.823T>C (p.Cys275Arg) SNV Likely pathogenic 376584 rs1057519983 17:7577115-7577115 17:7673797-7673797
39 TP53 NM_000546.5(TP53):c.824G>T (p.Cys275Phe) SNV Likely pathogenic 376582 rs863224451 17:7577114-7577114 17:7673796-7673796
40 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Likely pathogenic 17588 rs121913409 3:41266137-41266137 3:41224646-41224646
41 CTNNB1 NM_001904.4(CTNNB1):c.122C>T (p.Thr41Ile) SNV Likely pathogenic 17587 rs121913413 3:41266125-41266125 3:41224634-41224634
42 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr) SNV Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
43 TP53 NM_000546.5(TP53):c.517G>T (p.Val173Leu) SNV Likely pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
44 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
45 BRAF NM_001374258.1(BRAF):c.1900G>A (p.Asp634Asn) SNV Likely pathogenic 44813 rs397516896 7:140453155-140453155 7:140753355-140753355
46 TP53 NM_000546.5(TP53):c.395A>G (p.Lys132Arg) SNV Likely pathogenic 376625 rs1057519996 17:7578535-7578535 17:7675217-7675217
47 TP53 NM_000546.5(TP53):c.394A>C (p.Lys132Gln) SNV Likely pathogenic 376628 rs747342068 17:7578536-7578536 17:7675218-7675218
48 GNAS NM_000516.6(GNAS):c.602G>T (p.Arg201Leu) SNV Likely pathogenic 210045 rs121913495 20:57484421-57484421 20:58909366-58909366
49 GNAS NM_000516.6(GNAS):c.602G>A (p.Arg201His) SNV Likely pathogenic 15934 rs121913495 20:57484421-57484421 20:58909366-58909366
50 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908

Copy number variations for Adrenal Cortical Carcinoma from CNVD:

7 (show all 23)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 39293 10 11285212 16864223 Deletion Adrenocortical carcinoma
2 41923 10 26030462 27568983 Deletion Adrenocortical carcinoma
3 69267 12 54496959 54887816 Amplification Adrenocortical carcinoma
4 105388 16 79195214 80590034 Amplification Adrenocortical carcinoma
5 105796 16 82774218 84680399 Amplification Adrenocortical carcinoma
6 106027 16 85171711 86599633 Amplification Adrenocortical carcinoma
7 106330 16 87455812 88254372 Amplification Adrenocortical carcinoma
8 110643 17 33805634 34663603 Deletion Adrenocortical carcinoma
9 125811 19 15352798 16118051 Deletion Adrenocortical carcinoma
10 129302 19 45108448 45718366 Deletion Adrenocortical carcinoma
11 130528 19 49537470 50323207 Deletion Adrenocortical carcinoma
12 130657 19 50358143 53057498 Deletion Adrenocortical carcinoma
13 131131 19 53210832 53917176 Deletion Adrenocortical carcinoma
14 169573 3 142987765 144031265 Deletion Adrenocortical carcinoma
15 176088 3 46534671 47516603 Deletion Adrenocortical carcinoma
16 177057 3 52432656 53876467 Deletion Adrenocortical carcinoma
17 216378 6 91152410 95641352 Deletion Adrenocortical carcinoma
18 222196 7 150275058 151470304 Amplification Adrenocortical carcinoma
19 235763 8 144753570 146201712 Deletion Adrenocortical carcinoma
20 237149 8 21408650 22539377 Deletion Adrenocortical carcinoma
21 238033 8 29147511 31607545 Deletion Adrenocortical carcinoma
22 239018 8 36481039 39128088 Deletion Adrenocortical carcinoma
23 176572 3 49687490 50219610 Deletion Adrenocortical carcinoma

Expression for Adrenal Cortical Carcinoma

Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for Adrenal Cortical Carcinoma

Pathways related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 TP53 PRKAR1A PIK3CA NRAS IGF2 H3-3A
2
Show member pathways
12.97 TP53 PIK3CA NRAS GNAS CTNNB1 BRAF
3
Show member pathways
12.89 TP53 PIK3CA NRAS IGF2 GNAS CTNNB1
4
Show member pathways
12.81 TP53 PIK3CA NRAS CTNNB1 BRAF
5
Show member pathways
12.78 NRAS NR5A1 MC2R GNAS CTNNB1 BRAF
6
Show member pathways
12.74 PRKAR1A NRAS GNAS CTNNB1 BRAF
7
Show member pathways
12.73 PRKAR1A PIK3CA NRAS IGF2 GNAS BRAF
8
Show member pathways
12.63 TP53 PIK3CA NRAS CTNNB1 BRAF
9
Show member pathways
12.6 TP53 PIK3CA NRAS IGF2 CTNNB1 BRAF
10
Show member pathways
12.58 TP53 PIK3CA NRAS GNAS BRAF
11
Show member pathways
12.53 PIK3CA NRAS IGF2 GNAS CTNNB1 BRAF
12 12.53 TP53 PIK3CA NRAS IGF2 GNAS CTNNB1
13
Show member pathways
12.38 TP53 PIK3CA NRAS CTNNB1
14
Show member pathways
12.34 PIK3CA NRAS IGF2 CTNNB1 BRAF
15 12.29 TP53 PIK3CA NRAS MIR483 MIR214 MIR195
16 12.26 PIK3CA MC2R GNAS BRAF
17
Show member pathways
12.24 PIK3CA NRAS CTNNB1 BRAF
18
Show member pathways
12.07 TP53 PIK3CA NRAS BRAF
19
Show member pathways
12.03 PRKAR1A PIK3CA NRAS GNAS
20 11.98 TP53 PRKAR1A GNAS CTNNB1 BRAF
21 11.88 TP53 PIK3CA NRAS CTNNB1
22 11.84 TP53 PIK3CA NRAS CTNNB1
23 11.8 GNAS CTNNB1 BRAF
24
Show member pathways
11.75 PIK3CA NRAS BRAF
25 11.68 TP53 NRAS BRAF
26 11.67 PIK3CA NRAS BRAF
27 11.65 TP53 PIK3CA NRAS
28
Show member pathways
11.65 PRKAR1A PIK3CA GNAS CTNNB1 BRAF
29 11.63 PIK3CA GNAS BRAF
30 11.61 PRKAR1A NRAS IGF2 GNAS BRAF
31 11.55 NRAS GNAS BRAF
32 11.41 TP53 PIK3CA NRAS IGF2 CTNNB1 BRAF
33 11.4 TP53 NRAS IGF2 CTNNB1 BRAF
34 10.97 PIK3CA GNAS BRAF

GO Terms for Adrenal Cortical Carcinoma

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.72 TP53 NR5A1 MIR511 CTNNB1 BRAF
2 multicellular organism growth GO:0035264 9.43 TP53 H3-3A GNAS
3 positive regulation of connective tissue replacement GO:1905205 9.37 MIR214 MIR195
4 gene silencing by miRNA GO:0035195 9.17 MIR511 MIR503 MIR483 MIR214 MIR195 MIR184
5 hair follicle placode formation GO:0060789 9.16 GNAS CTNNB1
6 insulin receptor signaling pathway via phosphatidylinositol 3-kinase GO:0038028 8.96 PIK3CA IGF2

Molecular functions related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR511 MIR503 MIR483 MIR214 MIR195

Sources for Adrenal Cortical Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....